Clinical Trial Update: A Prospective, Randomized, Open-Label, Cross-Over Study of Lokelma to Control Interdialytic Hyperkalemia [Phase 4]

View source ↗

Summary

Phase 4 randomized, open-label, cross-over study evaluating Lokelma for control of interdialytic hyperkalemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperkalemia

Drugs mentioned

• Lokelma (sodium zirconium cyclosilicate)

Snippet

Sponsor: NephroNet, Inc. | Conditions: Hyperkalemia | Phase 4 | Status: COMPLETED